BioXcel Therapeutics (BTAI) Misses Q3 EPS by 45c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q3 EPS of ($1.72), $0.45 worse than the analyst estimate of ($1.27). Revenue for the quarter came in at $341 thousand versus the consensus estimate of $625.81 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Morgan Stanley upgrades CDW on stronger AI-driven server demand